By Iain Gilbert
Date: Friday 10 Mar 2023
LONDON (ShareCast) - (Sharecast News) - Oncology consultancy Physiomics revealed on Friday that it had been awarded a further contract by existing client Bicycle Therapeutics.
Physiomics stated the project related to an undisclosed program and was expected to be completed in the company's current financial year.
The AIM-listed group did not disclose the value of the contract.
Chief executive Dr Jim Millen said: "We are delighted that Bicycle has chosen us to support this new project. Physiomics has been working with Bicycle since 2019 and has been involved in various Bicycle programs spanning discovery through clinical development. We look forward to working with this valued client once again."
As of 0850 GMT, Physiomics shares were untraded at 4.20p.
Reporting by Iain Gilbert at Sharecast.com
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 0.68p |
Change Today | -0.025p |
% Change | -3.57 % |
52 Week High | 1.85p |
52 Week Low | 0.63p |
Volume | 174,292 |
Shares Issued | 203.21m |
Market Cap | £1.37m |
Beta | 0.48 |
RiskGrade | 504 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
09:25 | 170,000 @ 0.69p |
09:09 | 4,292 @ 0.70p |
You are here: research